Separating The Good From The Great: A Checklist For Evaluating A CRO For Rare Disease Studies

Sponsors in the rare disease space face several common hurdles throughout the drug development process, such as small patient populations, limited disease data, patient enrollment and retention, and restricted site pools. However, with the assistance of the right CRO partner, these challenges can be transformed into viable solutions.

When launching an RFP, refer to this checklist to ensure comprehensive coverage of all aspects when evaluating potential research partners for the rare disease study. By doing so, the chances of selecting the ideal research partner who can address the unique requirements of a rare disease study will be maximized.